Poster
84
(#84) Physical, Mental, and Socioemotional Functional Improvement Following Valbenazine Treatment for Tardive Dyskinesia: a Case Series
Psych Congress 2025
Abstract: This case series describes clinical characteristics and changes in mental, socioemotional, and physical domains of individuals with tardive dyskinesia (TD) after valbenazine treatment. Prior research suggests TD can impair patient functioning. Valbenazine, a vesicular monoamine transporter 2 inhibitor, is approved and guideline-recommended for TD treatment.
Clinicians reported data for patients who started valbenazine between 1/1/2024-6/30/2024, completed ≥2 months of treatment, and had ≥1 follow-up visit. Questions on burden and improvement were based on patient chart data and clinician recall. Out of 315 individuals receiving valbenazine, 20 individuals receiving maintenance valbenazine (40-80mg) were randomly selected. 6 cases were chosen to highlight a variety of patient characteristics. At baseline, all 6 individuals (ages 31-78 years, 4 males, 2 females) were diagnosed with a psychiatric disorder (n=4 schizophrenia, n=2 mood disorder), had previous antipsychotic exposure, and were moderately/significantly impacted in ≥1 functional area. All had moderate/significant impact in social domain. Length of symptoms was 3-5 years for 5 individuals and 1 year for 1 individual; 2 individuals each were reported with mild, moderate, or severe movement symptoms.
All moderately/significantly improved in ≥1 functional area; most (5/6) had improvement in movement symptoms within 4 weeks of starting valbenazine. Social domain improved for all and was moderate/significant for 4 individuals. Among the 3 individuals employed, all improved in ability/willingness to work. Psychiatric condition improved for all. Antipsychotic adherence improved in 4 (1 unknown). This case series adds granularity to the growing body of evidence that improvement extends beyond movement symptoms following appropriate TD treatment.
Short Description: This research describes clinical characteristics and changes in physical, mental and socioemotional domains after valbenazine treatment for patients with tardive dyskinesia (TD). All 6 participants had a psychiatric disorder diagnosis and previous antipsychotic medication exposure. All participants improved in psychiatric condition and ≥1 functional area (eg, mouth/throat function, social, emotional) after valbenazine treatment. This case series provides additional evidence that improvement with valbenazine extends beyond TD movement symptoms.
Name of Sponsoring Organization(s): Neurocrine Biosciences, Inc.
Clinicians reported data for patients who started valbenazine between 1/1/2024-6/30/2024, completed ≥2 months of treatment, and had ≥1 follow-up visit. Questions on burden and improvement were based on patient chart data and clinician recall. Out of 315 individuals receiving valbenazine, 20 individuals receiving maintenance valbenazine (40-80mg) were randomly selected. 6 cases were chosen to highlight a variety of patient characteristics. At baseline, all 6 individuals (ages 31-78 years, 4 males, 2 females) were diagnosed with a psychiatric disorder (n=4 schizophrenia, n=2 mood disorder), had previous antipsychotic exposure, and were moderately/significantly impacted in ≥1 functional area. All had moderate/significant impact in social domain. Length of symptoms was 3-5 years for 5 individuals and 1 year for 1 individual; 2 individuals each were reported with mild, moderate, or severe movement symptoms.
All moderately/significantly improved in ≥1 functional area; most (5/6) had improvement in movement symptoms within 4 weeks of starting valbenazine. Social domain improved for all and was moderate/significant for 4 individuals. Among the 3 individuals employed, all improved in ability/willingness to work. Psychiatric condition improved for all. Antipsychotic adherence improved in 4 (1 unknown). This case series adds granularity to the growing body of evidence that improvement extends beyond movement symptoms following appropriate TD treatment.
Short Description: This research describes clinical characteristics and changes in physical, mental and socioemotional domains after valbenazine treatment for patients with tardive dyskinesia (TD). All 6 participants had a psychiatric disorder diagnosis and previous antipsychotic medication exposure. All participants improved in psychiatric condition and ≥1 functional area (eg, mouth/throat function, social, emotional) after valbenazine treatment. This case series provides additional evidence that improvement with valbenazine extends beyond TD movement symptoms.
Name of Sponsoring Organization(s): Neurocrine Biosciences, Inc.
